Home > Uncategorized > Eicosapentanoic Acid in Hypercholesterolemic Patients

Eicosapentanoic Acid in Hypercholesterolemic Patients

The JELIS trial was a prospective randomized clinical trial examining the addition of purified eicosapentanoic acid (EPA: 2 x 300 mg three times=1800 mg per day) in Japanese patients with hypercholesterolemia. 18645  patients were randomized.  There were secondary prevention and primary prevention subgroups.

The trial revealed a reduction in the composite end-point of major coronary events overall in the trial. The primary prevention arm effect size was similar but did not reach significance. The secondary prevention group did reach significance.

jelisoverall

The effect on lipids is shown below:

jelisoverall02

and subgroup analysis:

jelisoverall03

An analysis of the primary prevention arm was subsequently published.  There was a dose response relationship between risk factors and cardiac events. Patients with high triglycerides and low HDL appeared to have a significant benefit with effect size similar to overall trial.

 

 

 jelispp02
jelispp03jelispp03_001

Advertisements
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: